Safety Information and Unanticipated Problems Reporting

Similar documents
IOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities

Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute

Adverse Events in Clinical Trials: Definitions and Documentation

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial

12.0 Investigator Responsibilities

Investigator responsibilities for research conducted under the authority of the UTHSCSA Institutional Review Board (IRB)

Data Management in Clinical Trials

Vertex Investigator-Initiated Studies Program Overview

Comprehensive Study Documents List (Biomedical Studies)

Essential Standard Operating Procedures Sample Templates Table of Contents

Quality Monitoring Checklist

Reliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s)

Effective Date: October 2015

PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

Guidance on IRB Continuing Review of Research

CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives

Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager

TEMPLATE DATA MANAGEMENT PLAN

Yale Cancer Center Data and Safety Monitoring Committee Charter

Essential Documents for the Conduct of a Clinical Trial. Debra Dykhuis Associate Director RSO

Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects

Tracy Walker, RN, BSN, CCRP Research Nurse OHSU Knight Cancer Institute

Standard Operating Procedures

Topics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions

Health Products and Food Branch.

Guidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB

Adverse Events: Documenting, Recording, and Reporting

ROLE OF THE RESEARCH COORDINATOR Study Start-up Best Practices

INVESTIGATOR HANDBOOK

Principal Investigator and Sub Investigator Responsibilities

Data Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Guidance for Clinical Investigators, Sponsors, and IRBs

STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)

Medicine Safety Glossary

The Study Site Master File and Essential Documents

Good Documentation Practices

Quality Agreements: Contractual Commitments by CROs to Deliver High-Quality Work

Serious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE

Page 191 TITLE 21 FOOD AND DRUGS 355 1

STANDARD OPERATING PROCEDURES FOR GOOD CLINICAL PRACTICE

PREP Course #27: Medical Device Clinical Trial Management

Role of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.

Principal Investigator Responsibilities for Education and Social/Behavioral Researchers

Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research

A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky

Pre-Questions. Mastering Clinical Research July 29, 2015

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

University of California Davis. Investigator Manual. Revised March 10, 2016

Challenges in the Regulation of Pediatric Clinical Trials

DHHS/NIH/OD/OIR/OHSRP 1/2/2015

Investigational Drugs: Investigational Drugs and Biologics

IRB Submissions and Human Subjects Research Compliance. Georgia Health Sciences University

The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations

Clinical Trials and Safety Surveillance of Drugs in Development

CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS:

Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health

Clinical Investigator Inspections and FDA-483 Observations

Investigator Handbook to Human Research Activities. South Shore Hospital

Health Canada s GCP Compliance Program Part 2. GCP Information Sessions November 2010

QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH

CLINICAL RESEARCH ROLES CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES

CNE Disclosures. To change this title, go to Notes Master

Objectives. The Paper Tells the Story

Regulatory Binder Instructions 25 April 2016

11/10/2011. History of CBUs. 10-CBA providing access to unlicensed cord blood units. The FDA s involvement. The FDA s involvement, cont.

This policy applies to all clinical research conducted at Beaumont Health System.

Data Management Unit Research Institute for Health Sciences, Chiang Mai University

Marie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager

The Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

No Page 1 of 5. Issue Date 4/21/2014

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy

Guidelines for preparing Standard Operating Procedures (SOP) for Institutional Ethics Committee for Human Research

Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey

V. Quality and Network Management

Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance

GUIDELINES ON MEDICAL DEVICES

How To Write A Binder Tab

Nova Southeastern University Institutional Review Board Policies and Procedures

2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials

COUPONS.COM INCORPORATED CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

AAHRPP DOCUMENT # 84 UNIVERSITY OF ALABAMA HUMAN RESEARCH PROTECTIONS PROGRAM FORM: NOTIFICATION TO IRB OF EMERGENCY USE OF A TEST ARTICLE

Good Clinical Practice 101: An Introduction

This unit will provide the structure needed to achieve successful supervision and oversight of the study. We will explain the importance of an

STAR*D: Sequenced Treatment Alternatives to Relieve Depression Data Collection Procedures for Cognitive Therapists

A New Standard for Medical Device Adverse Event Classification

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS

Patient Handbook on Stem Cell Therapies

Electronic Medical Records and Source Data for Research: What s the Difference?

Medical Billing Human Research Studies Seminar Notes

The Ontario Cancer Research Ethics Board Overview

Transcription:

Safety Information and Unanticipated Problems Reporting

Objectives This presentation will address the following issues: What events must be promptly reported to the Quorum Review institutional review board When and how such events must be reported Why it is important to promptly report certain reports to the Board How to report serious events, major protocol deviations and other significant unanticipated problems to Quorum Review IRB.

Investigators confront a variety of events that may be reportable to the sponsor of the research or the IRB / REB Unrelated adverse events Expected adverse events Minor adverse events Significant adverse events Major protocol deviations Minor protocol deviations New safety information Unanticipated Problems

Sponsors and IRB / REBs have different regulatory reporting requirements Sponsor Regulations require sponsors to monitor all adverse events (AEs) experienced by a study s participants. IRB /REB Regulations require an IRB/REB to develop procedures to ensure prompt reporting of unanticipated problems involving risk to human subjects or others.

Sponsors monitor all adverse events experienced by a study s participants Sponsors monitor minor, serious, expected, unexpected, related and unrelated AEs Sponsor perform data analysis and trending for the study Sometimes sponsors delegate data monitoring to a separate entity, such as a data safety monitoring board ( DSMB ) Sponsors must report their findings at least annually to the FDA

Investigator reporting requirements to sponsors and IRB / REBs are different Sponsor Investigators generally must report all adverse events to the sponsor of the clinical trial. The investigator s reporting requirements are set forth in the protocol for the study. IRB / REB Investigators must report all unanticipated problems involving risk to human subjects or others to the IRB/ REB.

The definition of an unanticipated problem involving risk is left to the IRB / REB The regulations do not provide a definition for unanticipated problems involving risk IRB / REBs must establish their own definition and procedures for investigators to report unanticipated problems involving risk

Quorum s definition of an unanticipated problem An unanticipated problem involving risk is an unexpected event that: Potentially increases risk to participants or others; Adversely affects the rights, safety or welfare of the participants; or Adversely affects the integrity of the study The investigator s judgment is needed to identify an unanticipated problem involving risk

Prompt reporting of unanticipated problems allows the IRB / REB members to decide whether: The risk/benefit ratio of the study is still acceptable in light of this new information Modifications should be made to the study to minimize risk to participants Participants should be informed of potential risks or findings The study should be suspended or terminated

Quorum s policy regarding reportable events Quorum s position is that unanticipated events that possibly involve risk are reportable events that must be reported promptly to the IRB / REB A reportable event must be reported within 10 business days of the investigator becoming aware of the event Reportable events must be reported using Quorum s report forms.

Report only unanticipated problems involving risk to participants or others All Problems Encountered During a Clinical Investigation Unanticipated problems involving risk to participants or others Protocol Deviations Adverse Events

What events to report Serious Adverse Events Major Protocol Deviations Other reportable events as defined by Quorum (including new safety information and significant unanticipated problems)

What events to report a closer look Serious Adverse Events Major Protocol Deviations Other reportable events as defined by Quorum (including new safety information and significant unanticipated problems)

Quorum s definition of a Serious Adverse Event (SAE) A Serious Adverse Event (SAE) is an adverse event that, in the investigator s judgment is Serious, Unanticipated, and At least possibly related to the study product or device Unanticipated problems involving risk to participants or others Adverse Events Serious Adverse Events

What makes an SAE serious? In the investigator s judgment it Results in death Is life threatening (places the participant at immediate risk of death) Results in persistent or significant disability/incapacity (a substantial disruption of the participant s ability to conduct normal life functions), Results in, or prolongs an existing, inpatient hospitalization Is a congenital anomaly/birth defect, or Jeopardizes the participant or requires intervention to prevent one of the outcomes listed above

Quorum s policy on reporting serious adverse events to the IRB / REB An investigator should report to the IRB / REB all serious adverse events that occur at his or her site. Unanticipated problems involving risk to participants or others Adverse Events Serious Adverse Events

Investigators do not need to report minor, expected, or unrelated adverse events to the IRB / REB Minor Adverse Events Unanticipated problems involving risk to participants or others Adverse Events Examples of adverse events not reportable: A minor headache, even if probably caused by the study drug A worsening of the underlying disease condition, if such worsening was expected A MedWatch report that, in the PI s judgment, reports a risk that is probably not related to the PI s study

What events to report a closer look Serious Adverse Events Major Protocol Deviations Other reportable events as defined by Quorum (including new safety information and significant unanticipated problems)

Quorum s definition of a Major Protocol Deviation / Violation A Major Protocol Deviation, is a deviation that in the investigator s judgment: Increases risk to one or more participants; Adversely affects the safety, rights or welfare of one or more participants; or Adversely affects the integrity of the study Major Protocol Deviations/Violations Protocol Deviations Unanticipated problems involving risk to participants or others

Quorum s policy on reporting Major Protocol Deviations to the IRB / REB Major Protocol Deviations/Violations An investigator should report to the IRB / REB all Major Protocol Deviations/ Violations that occur at his or her site. Protocol Deviations Unanticipated problems involving risk and other reportable information

Report only Major Protocol Deviations to the IRB / REB Examples of Major Protocol Deviations: Significant dosing error Study procedures initiated before informed consent Failure to perform laboratory test Major Protocol Deviations/Violations Protocol Deviations Unanticipated problems involving risk and other reportable information

Don t report minor protocol deviations or violations to the IRB / REB Minor Protocol Deviations Protocol Deviations Unanticipated problems involving risk and other reportable information Examples of minor protocol deviations: Insignificant delay in performing study procedure (i.e. minor window violation) Failure to initial every page of a consent form Participant failure to return study diaries

What events to report a closer look Serious adverse events Major protocol deviations Other reportable events as defined by Quorum (including new safety information and significant unanticipated problems)

Additional reportable events Adverse audit results from a sponsor audit FDA Form 483 or Warning Letter Suspension or restriction of medical license Unfavorable publication in literature Unresolved participant complaints Incarceration of research participant Breach of confidentiality (e.g., loss of study records) Problem involving control of study product (e.g., lost shipment of study drug) Research personnel misconduct Updated product information citing new risks (e.g., revised Investigator Brochure) Data Safety Monitoring Board report FDA Public Health Advisory Early Study termination or marketing withdrawal

Must an investigator report other events to the IRB /REB? An investigator should maintain records (such as logs or line listings) of all adverse events, protocol deviations, etc according to instructions from the sponsor or site monitor At the time of periodic site review, the investigator should report to the IRB / REB whether the investigator believes the study or consent form should be modified in light of these events Do not submit logs or line listings of minor adverse events, minor protocol deviations, etc. to the IRB / REB.

What if the Sponsor instructs investigators to submit all adverse events to the IRB / REB? If Quorum receives a report about an event that is not a reportable event, Quorum generally will issue an acknowledgment of receipt to the site with a reminder that Quorum does not require reporting of such events

Review: Report only unanticipated problems involving risk All Problems Encountered During a Clinical Investigation Unanticipated problems involving risk to participant or others Protocol Deviations Adverse Events

Review: Examples of unanticipated problems involving risk to participants or others that should be reported Do report these types of events: Serious Adverse Event Major Protocol Deviation Unresolved research complaint re: participant injury Participant incarcerated Adverse FDA / Sponsor audit report MedWatch of IND Safety report of relevant event Unanticipated problems involving risk to participants or others Reportable Events Protocol Deviations Adverse Events

Review: Examples of unanticipated problems not to report to the REB All Problems Encountered During a Clinical Investigation Don t report these types of events: Minor protocol deviation Minor adverse event Resolved complaint re: study payment Unanticipated problems involving risk and other reportable information Adverse Events Protocol Deviations Non-Reportable Events

Use Quorum s report forms for reportable events Serious Adverse Event Report for SAEs Major Protocol Deviation/Violation Report for major protocol deviations Safety Information and Unanticipated Problem Cover Page for other reportable events reported by the Sponsor to the investigator (MedWatch Reports, IND Safety Reports, etc.) Unanticipated Problem Report for additional reportable events reported by the investigator

For more information Please link to Quorum s website for more guidance and to find Quorum s reporting forms www.quorumreview.com/investigators_general.asp